An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and
safety of GSK1120212 compared with docetaxel in the second line setting for subjects with
locally advanced or metastatic (Stage IV) Non-small cell lung cancer (NSCLC) harboring a KRAS
mutation who have failed one platinum-containing chemotherapy regimen. A small subset of
NSCLC subjects harboring BRAF, NRAS, or MEK1 mutations will be randomized in addition to the
primary KRAS population, for exploratory purposes.